Offsetting virulence and antibiotic resistance costs by MRSA

被引:68
作者
Collins, James [2 ]
Rudkin, Justine [1 ]
Recker, Mario [2 ]
Pozzi, Clarissa [3 ]
O'Gara, James P. [3 ]
Massey, Ruth C. [1 ]
机构
[1] Univ Bath, Dept Biol & Biochem, Bath, Somerset, England
[2] Univ Oxford, Dept Zool, Oxford OX1 3PS, England
[3] Univ Coll Dublin, Sch Biomol & Biomed Sci, Dublin 2, Ireland
基金
英国生物技术与生命科学研究理事会;
关键词
Staphylococcus aureus; MRSA; fitness costs; virulence costs; CASSETTE CHROMOSOME MEC; STAPHYLOCOCCUS-AUREUS; METHICILLIN RESISTANCE; FITNESS COST; EVOLUTION; IDENTIFICATION; ADAPTATION; INFECTION; ELEMENT;
D O I
10.1038/ismej.2009.151
中图分类号
Q14 [生态学(生物生态学)];
学科分类号
071301 [植物生态学];
摘要
The prevalence of diverse MRSA (methicillin-resistant Staphylococcus aureus) types in both hospital and community settings is a major health problem worldwide. Here we compare hospital-acquired MRSAs with large type II SCCmec elements with those prevalent in both hospital and community settings with smaller type IV SCCmec elements. We find that the type II but not the type IV SCCmec element causes the bacteria to reduce their levels of costly toxin expression. We compare the relative growth rates of these MRSA types and show that the type II SCCmec carrying MRSAs are more affected than those carrying type IV elements and from this we hypothesize that offsetting the costs associated with antibiotic resistance and toxin expression is why the type II are confined to hospital environments where antibiotic use, the prevalence of immunocompromised individuals and vector-mediated transmission is high. In contrast, those MRSAs that are also successful in the community can maintain their high levels of toxin expression due to a lower fitness burden associated with the smaller SCCmec element. The ISME Journal (2010) 4, 577-584; doi:10.1038/ismej.2009.151; published online 14 January 2010
引用
收藏
页码:577 / 584
页数:8
相关论文
共 29 条
[1]
ANDERSON R M, 1991
[2]
The biological cost of antibiotic resistance [J].
Andersson, DI ;
Levin, BR .
CURRENT OPINION IN MICROBIOLOGY, 1999, 2 (05) :489-493
[3]
Identification of factors contributing to T-cell toxicity of Staphylococcus aureus clinical isolates [J].
Collins, James ;
Buckling, Angus ;
Massey, Ruth C. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (06) :2112-2114
[4]
The molecular evolution of methicillin-resistant Staphylococcus aureus [J].
Deurenberg, R. H. ;
Vink, C. ;
Kalenic, S. ;
Friedrich, A. W. ;
Bruggeman, C. A. ;
Stobberingh, E. E. .
CLINICAL MICROBIOLOGY AND INFECTION, 2007, 13 (03) :222-235
[5]
The second national prevalence survey of infection in hospitals - Overview of the results [J].
Emmerson, AM ;
Enstone, JE ;
Griffin, M ;
Kelsey, MC ;
Smyth, ETM .
JOURNAL OF HOSPITAL INFECTION, 1996, 32 (03) :175-190
[6]
Fitness cost of SCCmec and methicillin resistance levels in staphylococcus aureus [J].
Ender, M ;
McCallum, N ;
Adhikari, R ;
Berger-Bächi, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2295-2297
[7]
Fowler VG, 2004, J INFECT DIS, V190, P1140, DOI 10.1086/423145
[8]
Pathogenesis of methicillin-resistant Staphylococcus aureus infection [J].
Gordon, Rachel J. ;
Lowy, Franklin D. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 :S350-S359
[9]
The emergence and evolution of methicillin-resistant Staphylococcus aureus [J].
Hiramatsu, K ;
Cui, L ;
Kuroda, M ;
Ito, T .
TRENDS IN MICROBIOLOGY, 2001, 9 (10) :486-493
[10]
Novel type v staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC [J].
Ito, T ;
Ma, XX ;
Takeuchi, F ;
Okuma, K ;
Yuzawa, H ;
Hiramatsu, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2637-2651